Choosing between surrogacy and IVF with donor eggs depends primarily on whether the intended mother can safely carry a pregnancy, since IVF with donor eggs is generally preferred if she can carry but needs healthy eggs, while surrogacy is necessary if carrying is medically dangerous or impossible. Surrogacy remains significantly more expensive and legally more complex, taking 5 to 6 times the cost and 14 to 18 months of timeline compared to donor-egg IVF.

According to Dr. Mohit Saraogi, an experienced IVF specialist at Saraogi Hospital, couples often confuse the two as interchangeable options, “they’re really not, one solves a uterine problem and the other solves an egg problem, and picking the wrong path adds years of unnecessary complication and cost to what should be a straightforward clinical decision.”

Both treatments often come up in the same fertility consultation despite resolving completely different clinical concerns, which is how many couples end up pursuing the longer, costlier option when the shorter one would have addressed the actual issue.

A structured infertility treatment evaluation resolves this uncertainty well before treatment begins, clarifying which of the two routes the underlying diagnosis genuinely requires and preventing avoidable financial and procedural commitments on the wrong path.

The clinical diagnosis alone dictates the appropriate route, since acting against diagnostic findings tends to result either in unnecessary legal and procedural burden or in a pregnancy the patient’s body cannot medically sustain.

• Uterus: Clinical presentations such as MRKH syndrome, extensive tubercular or post-surgical uterine damage, or any condition under which pregnancy becomes medically unsafe, restrict the workable pathway to surrogacy alone, given that donor-egg IVF does not address the underlying structural deficit regardless of donor-egg quality.
• Egg quality: A functional uterus paired with non-viable oocytes arising from premature ovarian failure, age-related ovarian decline, or two to three prior IVF cycles that failed on the woman’s own eggs, positions donor-egg ICSI treatment as the clinically appropriate protocol, since it shortens the treatment timeline meaningfully and lowers the overall financial commitment.
• Age factor: Patients over 42 with confirmed uterine health typically move from per-cycle success rates below 5 percent on own eggs to approximately 50 to 60 percent with donor eggs, which removes any clinical justification for surrogacy wherever the uterus itself remains structurally and functionally sound.
• Legal factor: Surrogacy eligibility in India in 2026 remains restricted to married Indian couples, NRIs, OCI cardholders, and widowed or divorced single women aged 35 to 45, whereas donor-egg IVF operates under the ART Act 2021 with considerably lighter documentation requirements and a broader eligible patient base.

Protocol transitions between the two options do occur in response to evolving diagnostic findings, which is why accurate patient understanding of related pregnancy outcomes such as first-trimester spotting holds particular relevance for women carrying a donor-egg pregnancy themselves.

References:

• Ministry of Health and Family Welfare — Surrogacy (Regulation) Amendment Rules, 2024
• National Institutes of Health — Donor oocyte IVF outcomes